4//SEC Filing
CoLucid Pharmaceuticals, Inc. 4
Accession 0000911916-17-000068
CIK 0001348649operating
Filed
Feb 28, 7:00 PM ET
Accepted
Mar 1, 12:12 PM ET
Size
15.0 KB
Accession
0000911916-17-000068
Insider Transaction Report
Form 4
Dallas Matthew D
Chief Financial Officer
Transactions
- Disposition to Issuer
Common Stock
2017-03-01$46.50/sh−37,500$1,743,750→ 0 total - Disposition to Issuer
Employee Stock Option (Right to Buy)
2017-03-01$36.50/sh−180,254$6,579,271→ 0 totalExercise: $10.00Exp: 2025-05-05→ Common Stock (180,254 underlying) - Disposition from Tender
Common Stock
2017-03-01$46.50/sh−2,708$125,922→ 0 total - Disposition to Issuer
Employee Stock Option (Right to Buy)
2017-03-01$38.94/sh−30,000$1,168,200→ 0 totalExercise: $7.56Exp: 2025-08-04→ Common Stock (30,000 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2017-03-01$39.75/sh−37,500$1,490,625→ 0 totalExercise: $6.75Exp: 2026-03-04→ Common Stock (37,500 underlying)
Footnotes (6)
- [F1]Includes 80 shares acquired under the CoLucid Pharmaceuticals, Inc. Employee Stock Purchase Plan through February 19, 2017.
- [F2]Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the "Merger Agreement"), by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Eli Lilly and Company ("Lilly") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these shares were tendered pursuant to the Merger Agreement in exchange for a cash payment of $46.50 per share in cash, without interest.
- [F3]These restricted stock units, which by their terms were convertible into common stock of the Issuer on a one-for-one basis, vesting in a series of 48 successive equal monthly installments with the first monthly installment vesting on the grant date and the future installments vesting on the first day of each calendar month, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $46.50 per share in cash, without interest.
- [F4]These options, which provided that 25% of the shares vested on May 5, 2016, and the remaining shares vesting in a series of 36 successive equal monthly installments upon completion of each additional month of service, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest.
- [F5]These options, which provided that 25% of the shares vested on August 4, 2016, and the remaining shares vesting in a series of 36 successive equal monthly installments upon completion of each additional month of service, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest.
- [F6]These options, which provided for vesting in a series of 48 successive equal monthly installments with the first monthly installment vesting on the grant date and the future installments vesting on the first day of each calendar month, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest.
Documents
Issuer
CoLucid Pharmaceuticals, Inc.
CIK 0001348649
Entity typeoperating
Related Parties
1- filerCIK 0001348649
Filing Metadata
- Form type
- 4
- Filed
- Feb 28, 7:00 PM ET
- Accepted
- Mar 1, 12:12 PM ET
- Size
- 15.0 KB